Could a transplant drug shrink dangerous blood vessel tangles?

NCT ID NCT02042326

Recruiting now Disease control Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether sirolimus, a drug used to prevent organ rejection, can shrink severe arteriovenous malformations (AVMs) and ease symptoms. About 50 people aged 2 and older with advanced AVMs will take the drug for a year. The goal is to see if the drug reduces AVM size by at least 30% and stops it from growing, but participants may need ongoing treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARTERIOVENOUS MALFORMATIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

arteriovenous hemangioma/malformation arteriovenous malformations of the brain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARTERIOVENOUS MALFORMATIONS

Contacts and locations

Locations

APHM
NOT_YET_RECRUITING

Marseille, 13000, France
APHP
NOT_YET_RECRUITING

Paris, 75000, France
CHRU Lille
NOT_YET_RECRUITING

Lille, 59000, France
CHU Amiens
RECRUITING

Amiens, 80000, France
CHU Bordeaux
NOT_YET_RECRUITING

Bordeaux, 33000, France
CHU Dijon
RECRUITING

Dijon, 21000, France
CHU Montpellier
NOT_YET_RECRUITING

Montpellier, 34000, France
CHU Nancy
NOT_YET_RECRUITING

Nancy, 54000, France
CHU Nice
NOT_YET_RECRUITING

Nice, 06000, France
CHU Strasbourg
NOT_YET_RECRUITING

Strasbourg, 67000, France
CHU Tours
NOT_YET_RECRUITING

Tours, 37000, France
HCL Lyon
RECRUITING

Lyon, 69000, France
UCL
NOT_YET_RECRUITING

Brussels, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.